Edesa Biotech, Inc. (EDSA)

Market Cap	12.33M
Revenue (ttm)	n/a
Net Income (ttm)	-7.19M
Shares Out	8.33M
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,682
Open	1.490
Previous Close	1.480
Day's Range	1.438 - 1.504
52-Week Range	1.275 - 4.490
Beta	0.13
Analysts	Strong Buy
Price Target	13.00 (+778.38%)
Earnings Date	Feb 13, 2026

About EDSA

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: EDSA
• Website: https://www.edesabiotech.com

Analyst Summary

According to 2 analysts, the average rating for EDSA stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 778.38% from the latest price.

Price Target

$13.0

(778.38% upside)

Analyst Consensus: Strong Buy